HomeCompareONCT vs O

ONCT vs O: Dividend Comparison 2026

ONCT yields 379.79% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ONCT wins by $7846.55M in total portfolio value
10 years
ONCT
ONCT
● Live price
379.79%
Share price
$0.53
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7846.59M
Annual income
$5,169,197,450.71
Full ONCT calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.15
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,102.74
Full O calculator →

Portfolio growth — ONCT vs O

📍 ONCT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodONCTO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ONCT + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ONCT pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ONCT
Annual income on $10K today (after 15% tax)
$32,282.57/yr
After 10yr DRIP, annual income (after tax)
$4,393,817,833.10/yr
O
Annual income on $10K today (after 15% tax)
$449.12/yr
After 10yr DRIP, annual income (after tax)
$4,337.33/yr
At 15% tax rate, ONCT beats the other by $4,393,813,495.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ONCT + O for your $10,000?

ONCT: 50%O: 50%
100% O50/50100% ONCT
Portfolio after 10yr
$3923.31M
Annual income
$2,584,601,276.72/yr
Blended yield
65.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ONCT
No analyst data
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.7% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ONCT buys
0
O buys
0
No recent congressional trades found for ONCT or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricONCTO
Forward yield379.79%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$7846.59M$34.2K
Annual income after 10y$5,169,197,450.71$5,102.74
Total dividends collected$7596.65M$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: ONCT vs O ($10,000, DRIP)

YearONCT PortfolioONCT Income/yrO PortfolioO Income/yrGap
1← crossover$48,679$37,979.49$10,818$608.16+$37.9KONCT
2$224,874$172,787.13$11,787$741.68+$213.1KONCT
3$986,585$745,969.70$12,946$911.00+$973.6KONCT
4$4,114,314$3,058,668.09$14,345$1,127.94+$4.10MONCT
5$16,323,283$11,920,966.77$16,056$1,409.05+$16.31MONCT
6$61,667,489$44,201,576.55$18,171$1,777.83+$61.65MONCT
7$222,048,216$156,064,002.73$20,820$2,268.21+$222.03MONCT
8$762,773,776$525,182,185.09$24,188$2,929.90+$762.75MONCT
9$2,502,234,339$1,686,066,398.09$28,533$3,837.11+$2502.21MONCT
10$7,846,588,193$5,169,197,450.71$34,235$5,102.74+$7846.55MONCT

ONCT vs O: Complete Analysis 2026

ONCTStock

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Full ONCT Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ONCT vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ONCT vs SCHDONCT vs JEPIONCT vs KOONCT vs MAINONCT vs STAGONCT vs ADCONCT vs NNNONCT vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.